SCHEMBL76474

SCHEMBL76474

Cc1ccc(C([NH])=O)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.62
CES2 O00748 3/20 0.62
CES1 P23141 3/20 0.62
LMNA P02545 3/20 0.62
SMN1; SMN2 Q16637 3/20 0.59
HTT P42858 3/20 0.54
NPSR1 Q6W5P4 3/20 0.54
TDP1 Q9NUW8 3/20 0.54
KMT2A Q03164 3/20 0.54
PKM P14618 2/20 0.54
ATM Q13315 2/20 0.54
HPGD P15428 2/20 0.54
MEN1 O00255 2/20 0.54
NLRP1 Q9C000 1/20 0.54
GAA P10253 1/20 0.54
NTSR1 P30989 1/20 0.54
SRD5A2 P31213 1/20 0.52
HDAC1 Q13547 1/20 0.52
HDAC6 Q9UBN7 1/20 0.52
GSK3B P49841 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4838009 0.79 CES2 (0.71) ALDH1A1CES2CES1LMNASMN1; SMN2
SCHEMBL9302245 0.78 MAPT (0.54) ALDH1A1LMNASMN1; SMN2TDP1KMT2A
SCHEMBL167254 0.77 CES2 (1.00) ALDH1A1CES2CES1LMNASMN1; SMN2
SCHEMBL52200 0.77 ALDH1A1 (1.00) ALDH1A1CES2CES1LMNASMN1; SMN2
SCHEMBL822185 0.77 ALDH1A1 (1.00) ALDH1A1CES2CES1LMNASMN1; SMN2
SCHEMBL12362778 0.76 ALDH1A1 (0.84) ALDH1A1CES2CES1LMNASMN1; SMN2
SCHEMBL1775710 0.76 ALDH1A1 (0.58) ALDH1A1CES2CES1LMNASMN1; SMN2
SCHEMBL6113243 0.74 ALDH1A1 (0.65) ALDH1A1CES2CES1LMNASMN1; SMN2
SCHEMBL213538 0.74 LMNA (0.60) ALDH1A1CES2LMNAHTTTDP1
4-Methylbenzoic Acid SCHEMBL11366477 0.74 ALDH1A1 (1.00) ALDH1A1CES2CES1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1983 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117298108-A Androgen receptor and glucocorticoid receptor dual-target inhibitor and application thereof 浙江师范大学 2023-12-29 CN claimed
US-20220213030-A1 AMINOGUANIDINE HYDRAZONES AS RETROMER STABILIZERS USEFUL FOR TREATING NEUROLOGICAL DISEASES OSPEDALE SAN RAFFAELE SRL (IT) 2022-07-07 US claimed
CN-114341103-A Aminoguanidinohydrazones as reverse transporter stabilizers useful for the treatment of neurological disorders 圣拉斐尔医院有限公司 2022-04-12 CN claimed
EP-3947344-A1 AMINOGUANIDINE HYDRAZONES AS RETROMER STABILIZERS USEFUL FOR TREATING NEUROLOGICAL DISEASES Ospedale San Raffaele Srl (IT) 2022-02-09 EP claimed
WO-2020201326-A1 AMINOGUANIDINE HYDRAZONES AS RETROMER STABILIZERS USEFUL FOR TREATING NEUROLOGICAL DISEASES OSPEDALE SAN RAFFAELE SRL (IT) 2020-10-08 WO claimed
EP-1912988-B1 7-SUBSTITUTED AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PRODUCTION METHOD AND USE THEREOF AVENTIS PHARMA SA (FR) 2014-04-16 EP claimed
US-8058290-B2 E.g., 1-[4-(3-amino-1H-pyrazolo[3,4-b]pyridin-6-yl)phenyl]-3-(2-fluoro-5-trifluoromethylphenyl)urea; and N-(6-{4-[3-(2-fluoro-5-trifluoromethylphenyl)ureido]-phenyl}-1H-pyrazolo[3,4-b]pyridin-3-yl))thiophene-3-carboxamide; kinase inhibitors, anticancer agents AVENTIS PHARMA S.A. (FR) 2011-11-15 US claimed
US-20080182844-A1 7-Substituted Aza-Indazoles, Compositions Containing Same, Production Method and Use Thereof AVENTIS PHARMA S.A. (FR) 2008-07-31 US claimed
EP-1912988-A1 7-SUBSTITUTED AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PRODUCTION METHOD AND USE THEREOF Aventis Pharma S.A. (FR) 2008-04-23 EP claimed
WO-2007017577-A1 7-SUBSTITUTED AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PRODUCTION METHOD AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2007-02-15 WO claimed
EP-0446748-A2 Use of perylenedyes for the preparation of write, print or copying materials RIEDEL-DE HAEN AKTIENGESELLSCHAFT (DE) 1991-09-18 EP claimed
US-4942232-A FOR PRINTING AND DYEING CELLULOSE FIBERS BASF AKTIENGESELLSCHAFT (DE) 1990-07-17 US claimed
US-4921887-A ANTIALLERGENS FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) 1990-05-01 US claimed
US-4751288-A COLORFASTNESS BASF AKTIENGESELLSCHAFT (DE) 1988-06-14 US claimed
US-4643849-A ANTIULCER, ANTISECRETORY AGENTS TOYAMA CHEMICAL CO., LTD. (JP) 1987-02-17 US claimed
US-4604460-A ANTIBIOTICS, BACTERICIDES SHIONOGI & CO., LTD. (JP) 1986-08-05 US claimed
US-4443598-A ANTIBIOTICS AND INTERMEDIATES SHIONOGI & CO., LTD. (JP) 1984-04-17 US claimed
US-4308380-A 2-Lower alkyl-2 or 3-cephem-4-carboxylic acid derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1981-12-29 US claimed
US-4122089-A Aminothiofluoran compounds, process for the production thereof, and recording elements containing the same SANKIO CHEMICAL CO., LTD. (JP) 1978-10-24 US claimed
US-3987026-A POLYESTERS CIBA-GEIGY CORPORATION (US) 1976-10-19 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220213030-A1 AMINOGUANIDINE HYDRAZONES AS RETROMER STABILIZERS USEFUL FOR TREATING NEUROLOGICAL DISEASES PARK7, HTT, HRH1 ALDH1A1 188/4885CES2 3439/4885CES1 4027/4885
US-20080182844-A1 7-Substituted Aza-Indazoles, Compositions Containing Same, Production Method and Use Thereof PRMT7, PRKACA, PRKX ALDH1A1 2144/4885CES2 2267/4885CES1 3077/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.